Structure Therapeutics
GPCR
38 hedge funds and large institutions have $346M invested in Structure Therapeutics in 2023 Q1 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.45% more ownership
Funds ownership: 0% → 13.45% (+13%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$62.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$41.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$24.7M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$22.1M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NCM
26
Nantahala Capital Management
New Canaan,
Connecticut
| $1.19M | +$1.17M | +50,000 | New |
|
27
Prudential Financial
Newark,
New Jersey
| $999K | +$987K | +42,000 | New |
|
28
TD Asset Management
Toronto,
Ontario, Canada
| $855K | +$845K | +35,946 | New |
|
29
Millennium Management
New York
| $844K | +$833K | +35,459 | New |
|
|
SFG
30
SVB Financial Group
Dallas,
Texas
| $841K | +$831K | +35,353 | New |
|
|
LCM
31
Lynx1 Capital Management
San Juan,
Puerto Rico
| $547K | +$540K | +23,000 | New |
|
|
UOC
32
UBS O'Connor
Chicago,
Illinois
| $525K | +$518K | +22,050 | New |
|
|
PIM
33
Platinum Investment Management
Sydney Australia 2000,
Australia
| $357K | +$352K | +15,000 | New |
|
|
PMEF
34
Point72 Middle East FZE
Dubai,
United Arab Emirates
| $202K | +$199K | +8,474 | New |
|
|
CSS
35
Cubist Systematic Strategies
Stamford,
Connecticut
| $19.2K | +$18.9K | +805 | New |
|
|
S
36
SignatureFD
Atlanta,
Georgia
| $2.38K | +$2.35K | +100 | New |
|
|
TRCT
37
Tower Research Capital (TRC)
New York
| $2K | +$2.35K | +100 | New |
|
38
Morgan Stanley
New York
| $262 | +$258 | +11 | New |
|
GPCR Hedge Fund Activity: Q1 2023 in Review
38 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q1 2023, worth a combined $346M.
Buyers outnumbered sellers: 38 funds opened new GPCR positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $62.2M.
- 38 institutional investors held Structure Therapeutics (GPCR) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $346M of Structure Therapeutics stock for Q1 2023.
- 38 funds opened new Structure Therapeutics positions in Q1 2023 and 0 closed out, a net change of +38 holders.
- The largest Structure Therapeutics buyer in Q1 2023 was Deep Track Capital, an estimated $62.2M added.
Based on aggregated 13F filings for Q1 2023.